Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population
Marius M. Hoeper (Hannover, Germany), Marius Hoeper, Nazzareno Galie, Joan Albert Barbera, Adaani Frost, Ardeschir Ghofrani, Valerie McLaughlin, Andrew Peacock, Gerald Simonneau, Jean-Luc Vachiery, Christiana Blair, Hunter Gillies, Julia Harris, Jon Langley, Lewis Rubin
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Session: Pulmonary hypertension: new treatment insights
Session type: Oral Presentation
Number: 4994
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Marius M. Hoeper (Hannover, Germany), Marius Hoeper, Nazzareno Galie, Joan Albert Barbera, Adaani Frost, Ardeschir Ghofrani, Valerie McLaughlin, Andrew Peacock, Gerald Simonneau, Jean-Luc Vachiery, Christiana Blair, Hunter Gillies, Julia Harris, Jon Langley, Lewis Rubin. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. Eur Respir J 2015; 46: Suppl. 59, 4994
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: